Advertisement

U.S. markets open in 5 hours

S&P Futures
4,127.00
+2.50(+0.06%)
Dow Futures
32,760.00
+23.00(+0.07%)
Nasdaq Futures
13,036.25
+4.75(+0.04%)
Russell 2000 Futures
1,914.90
+0.30(+0.02%)
Crude Oil
89.79
-0.71(-0.78%)
Gold
1,804.80
-7.50(-0.41%)

Advertisement

BioAtla, Inc. (BCAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

3.6100

-0.1300

(-3.48%)

At close: 04:00PM EDT

3.7900

+0.18

(+4.99%)

After hours:

06:19PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	3.7400
Open	3.7000
Bid	0.0000 x 1400
Ask	0.0000 x 800
Day's Range	3.3100 - 3.7200
52 Week Range	2.0100 - 43.2400
Volume	185,092
Avg. Volume	497,148

Market Cap	135.064M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-2.8450
Earnings Date	Aug 09, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	31.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCAB

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

BioAtla, Inc.
Daily – Vickers Top Buyers & Sellers for 06/10/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
2 months agoArgus Research

All

Zacks
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Advantage Solutions Inc. (ADV) Beats Q2 Earnings Estimates
  Zacks
- Grocery Outlet Holding Corp. (GO) Tops Q2 Earnings and Revenue Estimates
  Zacks
GlobeNewswire
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in 4Q22 Mecbotamab vedotin (BA3011) Undifferentiated Pleomorphic Sarcoma (UPS) and osteosarcoma Phase 2 part 2 enrollment anticipated to begin 4Q22 following requested written feedback from FDA; continuing to enroll additional cohorts Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data sup
- Wireless Telecom Group, Inc. (WTT) Reports Q2 Loss, Misses Revenue Estimates
  Zacks
- ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
  Zacks
GlobeNewswire
BioAtla to Participate in the 2022 BTIG Biotechnology Conference
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference, to be held in New York, NY Monday, August 8, 2022. 2022 BTIG Biotechnology Conference Format: Fireside chat Date: Monday, August 8,